Tuesday’s General Session and Spotlight Poster Discussion presentations


Estimated Read Time:

4 minutes

Tuesday, December 6
2:00 pm – 5:00 pm CT
Hall 3

2:00 pm – 2:15 pm CT — GS1-01: Race and clinical outcomes in the RxPONDER trial (SWOG S1007)
2:15 pm – 2:30 pm CT — GS1-02: Racial disparity in tumor microenvironment and outcomes in residual breast cancer treated with neoadjuvant chemotherapy
2:30 pm – 2:45 pm CT — Discussant for GS1-01 and GS1-02 – Lori Pierce, MD
2:45 pm – 3:00 pm CT — GS1-04: Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status
3:00 pm – 3:15 pm CT — GS1-05: Trial Assigning Individualized Options for Treatment (TAILORx): An update including 12-year event rates
3:15 pm – 3:30 pm CT — GS1-06: Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial
3:30 pm – 3:45 pm CT — GS1-07: Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207
3:45 pm – 4:00 pm CT — Discussant for GS1-06 and GS1-07 – Polly Niravath, MD
4:00 pm – 4:15 pm CT — GS1-09: Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes
4:15 pm – 4:30 pm CT — GS1-10: Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2- advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy

5:00 pm – 6:15 pm
Hemisfair Ballroom 1&2

David Haynes, PhD – Disparities in screening and outcomes
Elena Martinez, PhD – Race and outcomes
Tammie Denyse – Patient Perspective

PD1-01: The impact of structural racism on breast cancer stage at presentation
PD1-02: Evaluating racial and ethnic disparities in diagnostic breast imaging: A retrospective cohort study
PD1-03: Neighborhood deprivation and breast cancer mortality among black and white women
PD1-04: Neighborhood deprivation index and survival in breast cancer in the United States
PD1-05: Racial/ethnic segregation and inequities in metastatic breast cancer treatment initiation and overall survival
PD1-06: Black patients with triple negative breast cancer (TNBC) have enriched stromal tumor infiltrating lymphocytes (sTILs) and receive preferential benefit from neoadjuvant immunotherapy
PD1-07: Racial disparities in neoadjuvant chemosensitivity and survival in early breast cancer: A national database study
PD1-08: PAM50 and 21-gene recurrence scores in younger and Black women with breast cancer
PD1-09: Associations between the 21-gene oncotype DX recurrence score (RS), Ki67, and race in early breast cancer (EBC) using the National Cancer Database (NCDB)
PD1-10: Impact of race on clinical, socioeconomic, and genomic characteristics, clinical trial participation, and receipt of genotype-matched therapy among patients with metastatic breast cancer

5:00 pm – 6:15 pm
Stars at Night Ballrooms 1&2

Discussants: Sangeetha Reddy, MD & Justin M. Balko, MD, PhD

PD2-01: Local and lymphoid immune surveillance mechanisms in “exceptional survivors” of stage 4 cancers following standard of care chemo- and targeted therapies
PD2-02: Longitudinal local and peripheral immunologic changes associated with checkpoint inhibition response in murine models of breast cancer
PD2-03: Targeting TGF-β and over-expressing GM-CSF in the Tumor Microenvironment (TME) with AMUN-003 Inhibits Tumor Growth and Metastases and Augments Immune Checkpoint Inhibitor (ICI) Response in Triple Negative Breast Cancer (TNBC)
PD2-04: Preclinical development of CodaLytic™, a codon-modified influenza virus, as a novel virotherapeutic agent for breast cancer immunotherapy
PD2-05: CSF-1R antibody targeting therapy with combined metronomic chemotherapy enhances a B and T cell response for the treatment of metastatic triple negative breast cancer
PD2-06: Implications of heterogeneity in breast tumor cell MHC-I expression on immunity and therapeutic resistance
PD2-07: Tumor CD73 regulates zoledronate induced TIL accumulation into triple negative breast cancer
PD2-08: Targeting of eIF4A1 along with anti-PD-L1 therapy limits lung metastases efficaciously in triple-negative breast cancer
PD2-09: Characterization of the lymphovascular invasion microenvironment reveals immune response dichotomy
PD2-10: MiR-150 expression in breast cancer cells attract infiltration of lymphocytes to tumor microenvironment and is associated with better survival of the patients
PD2-11: Human cytomegalovirus reactivation in immunosuppressive Th2 tumor microenvironment facilitates brain metastatic outgrowth

5:00 pm – 6:15 pm
Stars at Night Ballrooms 3&4

Reshma Jagsi, MD, DPhil – Is timing everything?
Ryan M. Rhome, MD, PhD – PBI – Post, Pre and Primary

PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study
PD3-02: Withdrawn
PD3-03: Preoperative robotic radiosurgery for early breast cancer: results of the phase II ROCK trial (NCT03520894)
PD3-04: Locoregional stereotactic body radiotherapy in breast cancer patients unsuitable for surgical resection
PD3-05: Early results of the French multicenter, randomized SHARE trial comparing whole breast irradiation versus accelerated partial breast irradiation in postmenopausal women with early-stage breast cancer
PD3-06: Robotic stereotactic APBI for early-stage breast cancer: 2-year outcomes of a prospective multi-institutional trial